Cytochrome P450 inhibition to decrease dosage and costs of venetoclax and ibrutinib: A proof‐of‐concept case study
- 22 November 2022
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 89 (2) , 898-902
Abstract
The inhibition of cytochrome P450 (CYP) enzymes is the most frequent cause of drug–drug interactions. Many safe, inexpensive and widely available therapeutic drugs can inhibit CYP enzymes (e.g., azoles). Also, the specific potency of inhibition and the targeted CYP enzyme have been well described (e.g., itraconazole strongly inhibits CYP enzyme 3A4 and, in turn, CYP3A4 metabolizes venetoclax and ibrutinib). CYP enzyme inhibitors increase the plasma concentration of other drugs via shared metabolic pathways. We herein present the effects of inhibiting CYP enzymes with itraconazole–venetoclax for the treatment of refractory acute myeloid leukaemia, as well as itraconazole–ibrutinib to treat steroid‐refractory acute graft vs. host disease in the same patient. Both of the patient's conditions responded completely. This appears to be a feasible strategy that decreases treatment costs by 75%. Previous Food and Drug Administration recommendations and clinical data support these subsequent dose reductions. Eleven months after the transplant, the patient remains in complete response and with no minimal residual disease. Another patient had been effectively treated before with CYP enzyme inhibition prior to venetoclax–itraconazole administration for orbital myeloid sarcoma. Thus, this case study furthers information on the CYP enzyme inhibition strategy when associated with another costly drug, ibrutinib. The CYP enzyme inhibition strategy could be applied to many more anticancer drugs (e.g., ruxolitinib and ponatinib) and facilitate the availability of expensive oncological treatments in low‐ and middle‐income countries. Also, this strategy could be further generalized by using different CYP enzyme inhibitors with varied pharmacokinetic and pharmacodynamic properties (i.e., grapefruit, azoles and clarithromycin).Keywords
This publication has 14 references indexed in Scilit:
- Fluconazole Increases Ibrutinib ConcentrationAmerican Journal of Therapeutics, 2020
- Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissionsDrug Metabolism and Personalized Therapy, 2019
- How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHDBlood Advances, 2018
- A drug–drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignanciesLeukemia & Lymphoma, 2018
- THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: OverviewBritish Journal of Pharmacology, 2017
- Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL‐2 inhibitor, in patients with non‐Hodgkin lymphomaBritish Journal of Clinical Pharmacology, 2017
- Access to Cancer Therapeutics in Low- and Middle-Income CountriesAmerican Society of Clinical Oncology Educational Book, 2016
- Effects of Ketoconazole on the Pharmacokinetics of Ponatinib in Healthy SubjectsThe Journal of Clinical Pharmacology, 2013
- Clinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered AgentsClinical Infectious Diseases, 2009
- Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targetsJournal of Clinical Investigation, 2000